Francois Clavel

Summary

Country: France

Publications

  1. ncbi AIDS 2002. Virology: overview
    Francois Clavel
    Laboratoire de Recherche Antivirale, IMEA/INSERM, Hopital Bichat-Claude Bernard, Paris, France
    AIDS 16:S1-2. 2002
  2. ncbi HIV drug resistance
    Francois Clavel
    Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
    N Engl J Med 350:1023-35. 2004
  3. ncbi Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
  4. ncbi Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir
    Stephane Lastere
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:221-7. 2004
  5. ncbi Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure
    Gilles Raguin
    Service de Maladies Infectieuses, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 9:615-25. 2004
  6. ncbi Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
    Beatrice Labrosse
    INSERM U 552, Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 77:1610-3. 2003
  7. ncbi Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses
    Tamara Nora
    Unité de Recherche Antivirale, INSERM U 552, Universite Denis Diderot Paris 7, Paris F 75018, France
    Retrovirology 5:23. 2008
  8. ncbi Clinically validated genotype analysis: guiding principles and statistical concerns
    Francoise Brun-Vezinet
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:465-78. 2004
  9. ncbi In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations
    Armelle Goubard
    INSERM U552, Paris, France
    Antivir Ther 14:597-602. 2009
  10. ncbi Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir
    Elisabeth Dam
    VIRALLIANCE, Paris, France
    Antivir Ther 12:371-80. 2007

Collaborators

Detail Information

Publications21

  1. ncbi AIDS 2002. Virology: overview
    Francois Clavel
    Laboratoire de Recherche Antivirale, IMEA/INSERM, Hopital Bichat-Claude Bernard, Paris, France
    AIDS 16:S1-2. 2002
  2. ncbi HIV drug resistance
    Francois Clavel
    Unité de Recherche Antivirale, Institut National de la Sante et de la Recherche Medicale, Unité 552, Hopital Bichat Claude Bernard, Paris
    N Engl J Med 350:1023-35. 2004
  3. ncbi Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  4. ncbi Impact of insertions in the HIV-1 p6 PTAPP region on the virological response to amprenavir
    Stephane Lastere
    Laboratoire de Virologie, Hopital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:221-7. 2004
    ..In conclusion, these results suggest that insertions in the p6 region of HIV-1 gag gene may affect the VR, in highly pre-treated patients receiving an unboosted APV-containing regimen...
  5. ncbi Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure
    Gilles Raguin
    Service de Maladies Infectieuses, Hopital Saint Antoine, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 9:615-25. 2004
    ....
  6. ncbi Baseline susceptibility of primary human immunodeficiency virus type 1 to entry inhibitors
    Beatrice Labrosse
    INSERM U 552, Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 77:1610-3. 2003
    ....
  7. ncbi Functional diversity of HIV-1 envelope proteins expressed by contemporaneous plasma viruses
    Tamara Nora
    Unité de Recherche Antivirale, INSERM U 552, Universite Denis Diderot Paris 7, Paris F 75018, France
    Retrovirology 5:23. 2008
    ..Less information is available concerning the extent that envelope sequence diversity translates into a diversity of phenotypic properties, including infectivity and resistance to entry inhibitors...
  8. ncbi Clinically validated genotype analysis: guiding principles and statistical concerns
    Francoise Brun-Vezinet
    Hospital Bichat Claude Bernard, Paris, France
    Antivir Ther 9:465-78. 2004
    ....
  9. ncbi In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations
    Armelle Goubard
    INSERM U552, Paris, France
    Antivir Ther 14:597-602. 2009
    ....
  10. ncbi Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir
    Elisabeth Dam
    VIRALLIANCE, Paris, France
    Antivir Ther 12:371-80. 2007
    ..Evidence of synergistic inhibition of wild-type HIV has been reported for saquinavir with atazanavir or lopinavir...
  11. ncbi Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088)
    Muriel Vray
    INSERM EMI 0214, Universite Pierre et Marie Curie, Paris, France
    Antivir Ther 8:427-34. 2003
    ..To identify predictors of the virological response to antiretroviral therapy in patients in whom initial therapy has failed...
  12. ncbi Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial
    Christophe Piketty
    Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
    Antivir Ther 11:213-21. 2006
    ..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
  13. ncbi Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
    Elisabeth Dam
    INSERM U552, Paris, France
    PLoS Pathog 5:e1000345. 2009
    ..Further compensatory mutations render viral RC independent of the A431V or I437V mutations while their effect on resistance persists...
  14. ncbi Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients
    Beatrice Labrosse
    INSERM U552, Unité de Recherche Antivirale, Hopital Bichat Claude Bernard, Paris, France
    J Virol 80:8807-19. 2006
    ..Thus, the envelope genetic context appears to play a critical role in the selection of HR1 mutations and the expression of ENF resistance, thereby conditioning the evolution of HIV-1 under fusion inhibitor selective pressure...
  15. ncbi Contribution of recombination to the evolution of human immunodeficiency viruses expressing resistance to antiretroviral treatment
    Tamara Nora
    INSERM U 552, Universite Paris 7 Denis Diderot, Faculte de Medecine Xavier Bichat, Paris, France
    J Virol 81:7620-8. 2007
    ....
  16. ncbi Human immunodeficiency virus type 1: resistance to nucleoside analogues and replicative capacity in primary human macrophages
    Danielle Perez Bercoff
    Antiviral Research Unit, INSERM U552, Hopital Bichat Claude Bernard, 46 rue Henri Huchard, 75018 Paris, France
    J Virol 81:4540-50. 2007
    ....
  17. ncbi HIV resistance to raltegravir
    Francois Clavel
    INSERM U941, Institut Universitaire d Hematologie, Hopital Saint Louis, Paris, France
    Eur J Med Res 14:47-54. 2009
    ....
  18. ncbi Enhancement of the influenza A hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA)
    Bin Su
    INSERM U941, Génétique et Ecologie des Virus, Institut Universitaire d Hematologie, Hopital Saint Louis, Universite Paris Diderot Paris 7, Paris, France
    PLoS ONE 4:e8495. 2009
    ..In this study we have examined the impact of NA expression on influenza HA-mediated viral membrane fusion and virion infectivity...
  19. ncbi Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assay
    Beatrice Labrosse
    Institut Universitaire d Hematologie, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11036. 2010
    ..In particular, the extent that previous infection or vaccination by seasonal A/H1N1 viruses can elicit protective immunity against pandemic A/H1N1 is unclear...
  20. ncbi Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir
    Xavier Duval
    Service des Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Antimicrob Agents Chemother 46:570-4. 2002
    ..03 to 0.70) and 7.0 (range, 1.4 to 145), respectively. At week 24, 2 of 8 and 13 of 14 patients in groups A and B, respectively, had <200 HIV RNA copies/ml of plasma, including 4 of 5 patients infected with APV-resistant viruses...
  21. ncbi Counteraction of tetherin antiviral activity by two closely related SIVs differing by the presence of a Vpu gene
    Kristina Nikovics
    INSERM U941, Paris, France
    PLoS ONE 7:e35411. 2012
    ..denti and C. neglectus tetherins, resulting in a predominantly perinuclear localization...